About Repare Therapeutics
Repare Therapeutics is a company based in Montreal (Canada) founded in 2016 by Daniel Durocher, Agnel sfeir, and Frank Sicheri was acquired by Alexis Bio in November 2025. Repare Therapeutics has raised $165.5 million across 3 funding rounds from investors including TD Securities, Orbimed and Celgene. The company has 129 employees as of December 31, 2024. Repare Therapeutics offers products and services including RP-3467, RP-1664, Lunresertib, and Camonsertib. Repare Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter Montreal, Canada
- Employees 129 as on 31 Dec, 2024
- Founders Daniel Durocher, Agnel sfeir, Frank Sicheri
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Repare Therapeutics Inc.
-
Annual Revenue
$53.48 M (USD)4.58as on Dec 31, 2024
-
Net Profit
-$84.69 M (USD)9.71as on Dec 31, 2024
-
EBITDA
-$89.29 M (USD)20.85as on Dec 31, 2024
-
Total Equity Funding
$165.5 M (USD)
in 3 rounds
-
Latest Funding Round
$15 M (USD), Series B
May 26, 2020
-
Investors
TD Securities
& 11 more
-
Employee Count
129
as on Dec 31, 2024
-
Acquired by
Alexis Bio
(Nov 14, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Repare Therapeutics
Repare Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RPTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Repare Therapeutics
Repare Therapeutics offers a comprehensive portfolio of products and services, including RP-3467, RP-1664, Lunresertib, and Camonsertib.
Inhibitor targeting Polθ ATPase for cancer treatment
Inhibitor for PLK4 in oncology applications
PKMYTI inhibitor for cancer therapy development
ATR inhibitor used in precision oncology trials
People of Repare Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Repare Therapeutics
Repare Therapeutics has successfully raised a total of $165.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $15.0M
-
First Round
First Round
(22 Jun 2017)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Series B - Repare Therapeutics | Valuation | Bristol-Myers Squibb |
|
| Sep, 2019 | Amount | Series B - Repare Therapeutics | Valuation | Cowen | |
| Jun, 2017 | Amount | Series A - Repare Therapeutics | Valuation | MPM Capital , Versant Ventures |
Investors in Repare Therapeutics
Repare Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include TD Securities, Orbimed and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location | |
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location |
Investments & Acquisitions by Repare Therapeutics
Financial Statements - Repare Therapeutics
Repare Therapeutics Comparisons
Competitors of Repare Therapeutics
Repare Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Frequently Asked Questions about Repare Therapeutics
Repare Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Repare Therapeutics is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Repare Therapeutics is a funded company, having raised a total of $165.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $68M, raised on Jun 22, 2017.
As of Dec 31, 2024, the latest employee count at Repare Therapeutics is 129.
Annual revenue of Repare Therapeutics is $53.48M as on Dec 31, 2024.
Repare Therapeutics was founded in 2016 in Montreal, Canada, within the biotechnology sector. Targeted therapies addressing genetic alterations in selected tumors are developed using a genome-wide, CRISPR-enabled SNIPRx platform. This approach systematically identifies cancer treatments focused on genomic instability, such as DNA damage repair. The lead candidate, PolQ, inhibits Polθ to target tumors with mutations in homology-directed repair genes. Operations emphasize precision oncology for oncology applications.
Repare Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Repare Therapeutics offers RP-3467, RP-1664, Lunresertib, and Camonsertib.
Yes, Repare Therapeutics is publicly traded on NASDAQ under the ticker symbol RPTX.
Repare Therapeutics has 12 investors. Key investors include TD Securities, Orbimed, Celgene, BDC, and Bristol-Myers Squibb.
The ticker symbol of Repare Therapeutics is RPTX on NASDAQ.